Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database

OBJECTIVES: Subcutaneous tumour necrosis factor alpha TNFαinhibitors (SC-TNFis) such as golimumab (GLM), adalimumab (ADA), etanercept (ETA) and certolizumab pegol (CZP) have been used for many years for the treatment of inflammatory arthritis. Non-adherence to therapy is an important modifiable fact...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Bhoi, Peter, Bessette, Louis, Bell, Mary J, Tkaczyk, Cathy, Nantel, Francois, Maslova, Karina
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Rheumatology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5623530/
https://ncbi.nlm.nih.gov/pubmed/28928177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2017-015872
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados